Immuron granted US Travelan patent
Immuron (ASX:IMC) has been granted a new US patent covering products including Travelan, its preventative treatment for travellers’ diarrhoea.
The US Patents and Trademarks Office has issued a Notice of Allowance covering one of the company’s patent claims.
Immuron’s patent claims are focused on methods of treating enteric diseases with the company’s hyperimmune colostrum platform technology.
The company is also using the platform to develop treatments for other enteric diseases, including C. difficile and nonalcoholic steatohepatitis (NASH), and the newly granted patent also encompasses these other projects.
“It is reassuring to have this patent in place ... as we continue to progress with our substantive discussions in the United States for the commercialisation of Travelan and related products in the world’s largest market for pharmaceuticals,” Immuron CEO Amos Meltzer said.
“We look forward to achieving further patents around our core technologies in the USA and other key jurisdictions.”
Immuron (ASX:IMC) shares were trading 40% higher at $0.007 as of around 2 pm on Wednesday.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
